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Abstract
Panic disorder (PD) affects about four million Europeans, with women affected twice as likely as men, causing
substantial suffering and high economic costs. The etiopathogenesis of PD remains largely unknown, but both genetic
and environmental factors contribute to risk. An epigenome-wide association study (EWAS) was conducted to
compare medication-free PD patients (n = 89) with healthy controls (n = 76) stratiﬁed by gender. Replication was
sought in an independent sample (131 cases, 169 controls) and functional analyses were conducted in a third sample
(N = 71). DNA methylation was assessed in whole blood using the Inﬁnium HumanMethylation450 BeadChip. One
genome-wide association surviving FDR of 5% (cg07308824, P = 1.094 × 10-7, P-adj = 0.046) was identiﬁed in female
PD patients (N = 49) compared to controls (N = 48). The same locus, located in an enhancer region of the HECA gene,
was also hypermethylated in female PD patients in the replication sample (P = 0.035) and the signiﬁcance of the
association improved in the meta-analysis (P-adj = 0.004). Methylation at this CpG site was associated with HECA mRNA
expression in another independent female sample (N = 71) both at baseline (P = 0.046) and after induction by
dexamethasone (P = 0.029). Of 15 candidates, 5 previously reported as associated with PD or anxiety traits also showed
differences in DNA methylation after gene-wise correction and included SGK1, FHIT, ADCYAP1, HTR1A, HTR2A. Our study
examines epigenome-wide differences in peripheral blood for PD patients. Our results point to possible sex-speciﬁc
methylation changes in the HECA gene for PD but overall highlight that this disorder is not associated with extensive
changes in DNA methylation in peripheral blood.
Introduction
Panic disorder (PD) is the most disabling anxiety dis-
order, causing substantial suffering, and high economic
and social costs. It affects about four million Europeans
(12-month prevalence estimate is about 2%) with women
being twice as likely to be affected as men1. PD is char-
acterized by sudden episodes of acute anxiety (panic
attacks) occurring without any apparent reason. It can be
accompanied by a persistent concern of having additional
attacks or worry about the possible consequences of the
attacks (e.g., suffering of a heart attack, dying, losing
control) and signiﬁcant behavioral changes to avoid future
panic attacks2. First onset for PD is in adolescence and
early adulthood2 and it is highly co-morbid with other
mental disorders, especially agoraphobia3.
Despite the substantial long-term disability, PD appears
to be underdiagnosed and undertreated in mental health
settings. The overall heritability of PD is substantial with
heritability estimates up to 48%4. Genetic studies (gen-
ome-wide as well as candidate gene approaches) have
identiﬁed some loci possibly contributing to disease risk
such as variants in the TMEM132D locus5, 6, COMT7,
CRHR18, SLC6A4, MAOA, HTR1A9, but overall genetic
linkage or association signals are usually not consistently
replicated.
Exposure to negative life events are the complementing
risk factors to genetics so that both genetic and envir-
onmental components are likely important mechanisms
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inﬂuencing disease risk10. The differential contribution of
environmental and genetic factors in risk for anxiety
disorders, personality disorders, alcohol use disorders has
been previously supported by epidemiologic and twin
studies11–13. Adverse life events have been shown to
associate with speciﬁc epigenetic modiﬁcations, such as
DNA methylation, which may mediate the lasting cellular
consequences of these exposures in psychiatric dis-
orders14, also in the context of gene–environment inter-
actions15. Exploring DNA methylation may thus be able
to give an integrated view of both environmental and
genetic risk factors. While epigenetic changes including
DNA methylation are mainly tissue speciﬁc, some sites
show cross tissue relevance16, 17 and furthermore changes
in peripheral tissues such as blood could serve as potential
biomarker for disease risk.
To date, a few studies have investigated differences in
DNA methylation in candidate genes in PD5, 18–21.
Recently, one epigenome-wide study of DNA methylation
in a relatively small Japanese PD case-control sample (48
patients vs. 48 controls) detected signiﬁcant associations
at 40 sites with overall small methylation differences22. So
far, studies in the European population are lacking. To
perform such a study in two independent samples of
patients with PD vs. control was the aim of our study. To
reduce confounding due to effects of drug treatment, both
patients and controls were free of psychotropic medica-
tion. Given that both the prevalence of PD as well as DNA
methylation pattern show large gender differences23, a
gender-stratiﬁed analysis was undertaken and com-
plemented by a meta-analysis.
Previous studies report that hits identiﬁed in genome-
wide association studies (GWAS) show changes in DNA
methylation in peripheral blood, e.g., in schizophrenia24
or bipolar disorder25. For this reason, in addition to an
unbiased approach, we also investigated DNA methyla-
tion changes in candidate genes that have emerged from
genome-wide or candidate gene studies for PD, anxiety
disorders or anxiety related phenotypes either in humans
or animals5,26, 27.
PD has a high comorbidity rate not only with other
psychiatric disorders like agoraphobia and depression, but
also with other medical conditions, e.g., cardiovascular
disorders, asthma and epilepsy1. DNA methylation age
has been previously correlated with morbidity and mor-
tality28–31. Therefore, we also investigated whether age
acceleration was occurring in PD patients compared to
controls.
Materials and Methods
Max Planck Institute of Psychiatry PD cohort
PD patients included in the discovery and replication
sample were recruited in the anxiety disorders outpatient
unit at the MPIP in Munich5. PD was the primary
diagnosis; mild secondary depression was allowed (Table
1). The diagnosis was ascertained by trained psychiatrists
according to the Diagnostic and Statistical Manual of
Mental Disorders (DSM)-IV criteria. All patients under-
went the Structured Clinical Interviews for DSM-IV
(SCID I and II). PD due to a medical or neurological
condition or the presence of a comorbid Axis II disorder
was an exclusion criterion. All patients underwent a
Table 1 Characteristics of the participants included in the
study
Variable Controls Cases Total
Discovery
Participants, N (%) 76 (46%) 89 (54%) 165
Male, N (%) 28 40 68 (41%)
Female, N (%) 48 49 97 (59%)
Age, years (SD) 37 (7.5) 36 (10.4)
Diagnosis None PDA 72%
PD 28%
Comorbidity:MDD 13.5%
Replication
Participants, N (%) 169 (56%) 131 (44%) 300
Male, N (%) 48 48 96 (32%)
Female, N (%) 121 83 204 (68%)
Age, years (SD) 38 (7.2) 38 (11.6)
Diagnosis None PDA 61%
PD 39%
Comorbidity:MDD 13%
Meta-analysis
Participants, N (%) 245 (55%) 220 (45%) 465
Male, N (%) 76 88 164 (34%)
Female, N (%) 169 132 301 (66%)
Age, years (SD) 38 (7.3) 38 (11)
Diagnosis None PDA 65%
PD 35%
Comorbidity:MDD 13%
Dex-treatment study
Participants, N (%) 29 (41%) 42 (59%) 71
Male, N (%) 0 0 0
Female, N (%) 29 42 71
Age, years (SD) 44 (11.4) 44 (13.7)
Diagnosis None MDD
PDA panic disorder with agoraphobia, PD panic disorder without agoraphobia,
MDD major depressive disorder
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thorough medical examination including EEG, ECG and
detailed hormone laboratory assessment.
Control subjects were recruited from a Munich-based
community sample and screened for the absence of axis I
psychiatric disorders using the Munich version of the
Composite International Diagnostic Interview32. Controls
were age-matched and sex-matched with patients.
To reduce confounding due to effects of drug treatment,
both patients and controls were free of psychotropic
medication for at least 4 weeks before the blood draw. All
subjects were Caucasian and provided written informed
consent. The Ethics Committee of the Ludwig Max-
imilians University, Munich, Germany, in accordance
with the Declaration of Helsinki approved all procedures.
Microarray processing and quality control in the MPIP PD
cohort
Genomic DNA was extracted from peripheral blood
using the Gentra Puregene Blood Kit (Qiagen). DNA
quality and quantity was assessed using NanoDrop 2000
Spectrophotometer (Thermo Scientiﬁc) and Quant-iT
Picogreen (Invitrogen). To minimize batch effects, sam-
ples were randomized with respect to case-control status,
sex and age.
Genomic DNA was bisulﬁte converted using the
Zymo EZ-96 DNA Methylation Kit (Zymo Research)
and DNA methylation levels were assessed for >480,000
CpG sites using the Illumina HumanMethylation450
BeadChip array. Hybridization and processing were
performed according to the instructions of the
manufacturer.
The Bioconductor R package minﬁ (version 1.10.2) was
used for the quality control of methylation data including
intensity read outs, normalization, cell type composition
estimation, β-value and M-value calculation. Outliers, i.e.,
samples whose behavior deviated from that of others in
terms of median intensity, were excluded from the ana-
lysis (N= 3 in the discovery sample, N= 5 in the repli-
cation sample) as well as samples with a discordant
methylation-predicted vs. reported sex (N= 1 in the
replication sample).
Failed probes were excluded based on a detection P-
value larger than 0.01 in >50% of the samples. X and Y
chromosome were removed to avoid a possible gender
effect and also non-speciﬁc binding probes33. We also
excluded probes if single nucleotide polymorphisms
(SNPs) were documented in the interval for which the
Illumina probe is designed to hybridize. Probes located
close (10 bp from query site) to a SNP which had a minor
allele frequency of ≥0.05, as reported in the 1000 Gen-
omes Project, were also removed. This yielded a total of
around 425,000 CpG sites in the discovery and replication
sample for further analysis.
The data were then normalized with functional nor-
malization (FunNorm)34, an extension of quantile nor-
malization included in the R package minﬁ.
Batch effects were identiﬁed by inspecting the associa-
tion of principal components of the methylation levels
with possible technical batches using linear regressions
and visual inspection of principal component analysis
plots using the Bioconductor R package shinyMethyl
(version 0.99.3). Identiﬁed batch effects (i.e., bisulﬁte
conversion plate and plate position) were removed using
the Empirical Bayes’ method ComBat35. Batch corrected
M-values after ComBat were used for all further statistical
analyses.
Epigenome-wide association analysis
Linear regression models were ﬁt for each probe to test
for a case vs. control difference within the R package
MatrixEQTL (version 2.1.1)36. Sex, age and imputed white
blood cell distribution from the Houseman projection37
were included as covariates. Population stratiﬁcation was
investigated using multidimensional scaling and could not
be observed (Supplementary Fig. S1). Signiﬁcance after
multiple testing was adjusted using false discovery rate
(FDR) of 5%. As a ﬁrst step all the samples were analyzed
together (Table 1) but, given the higher prevalence of PD
in females, we performed a sex-stratiﬁed analysis, ﬁrst in
the discovery and then in the replication sample. A ﬁxed-
effect meta-analysis across both samples was performed in
Plink v1.938 following identiﬁcation of hits in the indivi-
dual analyses.
In order to investigate whether we can ﬁnd clusters of
association in the epigenome-wide analysis, we performed
the differentially methylated region (DMR) analysis on the
combined results from both samples based on the input of
individual P-values of at least 5e-05 and within 500 bp
using Comb-P39.
Targeted gene analysis
A high number of studies showed mostly single SNP
associations in different genes with PD, however, the
replicability of these ﬁndings was low. Therefore, we used
three lines of approaches to select candidate genes for the
targeted methylome analysis: (1) candidate genes from
human genetic studies conﬁrmed in the recent meta-
analysis of different international PD cohorts
(TMEM132D, COMT, NPSR1 and HTR2A)7, (2) and/or
having additional evidence from translational studies for
anxiety and stress related-phenotypes (CRH, CRHR1,
ADCYAP1, ADCYAP1R1, FKBP5, SGK1, BDNF, HTR1A)8,
40–46 and lastly, (3) genes containing loci with previous
evidence for differential methylation in PD and anxiety
disorders (GAD1, OXTR)20, 47. All the genes examined (N
= 15) showed previous evidence of association with
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stress-related phenotypes not only in clinical (human)
studies but also in preclinical (animal) studies5,26,27, 48–52.
The CpGs lying within the target genes were selected
from the meta-analysis results of the epigenome-wide
association study (EWAS) and FDR correction of 5% was
applied for the number of CpGs included in the gene.
Disease association analysis
To investigate a possible enrichment for speciﬁc path-
ways, we conducted a disease association analysis using
Web Gestalt53, 54, DAVID55, 56 and the R-package
DOSE57.
Tested genes for a disease enrichment were annotated
from CpG sites with P-value< 0.001 in the meta-analysis
results of the cases vs. controls EWAS in the whole
sample (Ngenes= 312), in the female subset (Ngenes= 428)
and in the male subset (Ngenes= 379). The analysis was
background corrected for the Illumina HumanMethyla-
tion450 BeadChip array annotated genes.
DNA Methylation age calculation
DNA methylation age was calculated from peripheral
blood of patients and controls included in the discovery
(N= 165) and replication sample (N= 300). DNA
methylation-based age prediction was performed using
the R code and statistical pipeline developed by Hor-
vath58. This predictor was developed using 82 Illumina
DNA methylation array datasets (n= 7,844) involving 51
healthy tissues and cell types58. The raw data were nor-
malized using BMIQ normalization method59 imple-
mented in the Horvath DNA methylation-based age
predictor R script58. We then tested whether epigenetic
age acceleration (Δ-age), calculated by subtracting the
actual chronological age from DNA methylation age58,
was associated with case-control status. Since DNA
methylation age is calculated from raw beta values,
technical batches identiﬁed for discovery and replication
sample (96-well plate) were included as covariates in the
linear regression model together with age, sex and cell
counts (Houseman and Horvath cell counts, speciﬁcally:
PlasmaBlast, CD8pCD28nCD45Ran, CD8.naive, CD4T,
NK, Mono, Gran).
MPIP dexamethasone treatment study
Glucocorticoid-induced methylation and gene expres-
sion changes were examined in an independent sample of
71 Caucasian female subjects (29 healthy probands and 42
depressed) recruited at the MPIP. Recruitment strategies
and characterization of participants have been previously
described60. Baseline whole blood samples were obtained
at 6 pm after 2 h of fasting and abstention from coffee and
physical activity (baseline). Subjects then received 1.5 mg
oral dexamethasone (DEX) and a second blood draw was
performed at 9 pm 3 h after DEX ingestion (post-DEX).
The study was approved by the local ethics committee and
all individuals gave written informed consent.
DNA methylation and gene expression arrays in the MPIP
dexamethasone treatment study
Genomic DNA was extracted from whole blood using
the Gentra Puregene Blood Kit (QIAGEN) and processed
as for the MPIP PD cohort. DNA methylation levels were
assessed for >480,000 CpG sites using the Illumina
HumanMethylation450 BeadChip arrays. Whole blood
RNA was collected using PAXgene Blood RNA Tubes
(PreAnalytiX), processed as described previously60. Blood
RNA was hybridized to Illumina HumanHT-12 v3 and v4
Expression BeadChips arrays. All methylation and gene
expression array probes have been subjected to an
extensive quality control including ﬁltering by low p-
detection value, normalization (FunNorm for methylation
and VSN for gene expression data) and batch correction
with ComBat as previously described in ref. 61. Cellular
composition was estimated by using CellCode62.
Statistical analysis in the MPIP dexamethasone treatment
study
Methylation levels of cg07308824 were tested for asso-
ciation with gene expression levels of the HECA mRNA
(ILMN_1770667) using a linear mixed effects model
within the lme4 package63.
Results
Genome-wide methylation differences in discovery and
replication samples
Genome-wide associations were performed in the dis-
covery sample, combined as well as stratiﬁed by gender.
While no association survived correction for multiple
testing in the overall samples and the male subset, one
genome-wide association, cg07308824, surviving FDR of
5% (P= 1.094× 10-7, P-adj= 0.046) was observed in the
female-only discovery sample. QQ plots for each of the
analyses are presented in the Supplementary Figs. S2–S3.
cg07308824 is located in the promoter of the HECA gene
and was hypermethylated in female PD patients (N= 49)
compared to controls (N= 48). The association and the
direction of the association could be replicated in the
second sample (P= 0.035) and yielded a combined P-
value of 1.651e-08 in the meta-analysis, that would again
survive correction for multiple testing (P-adj= 0.004)
(Figs. 1, 2).
The DMR analysis using Comb-P revealed no sig-
niﬁcantly associated regions.
Targeted gene analysis
The targeted gene analysis (see Supplementary Tables
S1–S15 for the complete list of genes tested) using the
meta-analysis results, yielded in females one signiﬁcant
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CpG each (surviving 5% FDR correction over the CpGs in
the gene) in ADCYAP1 (P-adj= 0.010) and HTR1A (P-adj
= 0.041) (Supplementary Fig. S4). The same analysis
yielded one signiﬁcant CpG in SGK1 (P-adj= 0.035)
(Supplementary Fig. S5) in the whole sample and in males
in fragile histidine triad (FHIT, P-adj= 0.010) and two
signiﬁcant CpGs in HTR2A (P-adj= 0.015 and P-adj=
0.029) (Supplementary Fig. S6) (Table 2). Single nominal
associations have been found in the genes ADCY1P1R1,
BDNF, COMT, CRH, CRHR1, GAD1, OXTR and
TMEM132D. No differential methylation was detected for
NPSR1 between cases and controls.
Disease association analysis
An enrichment for psychiatric disorders could be found
in the whole sample (bipolar disorder, P= 1.9e-2; mental
disorders, P= 2.5e-2) and in females (response to anti-
psychotic treatment, P= 5.3e-2; ADHD, P= 9.5e-2) using
DAVID55, 56.
Functional characterization of signiﬁcant results
To assess the functionality of the signiﬁcant CpG
methylation site, association of methylation levels with
gene expression of the HECA mRNA was tested. Methy-
lation at this CpG site was associated with mRNA
expression of HECA (ILMN_1770667) both at baseline (P
= 0.046) and after induction by dexamethasone (P=
0.029) (Fig. 3). Gene expression was signiﬁcantly altered
in the sample following dexamethasone induction (P=
8.78e-05) but not DNA methylation (P= 0.796), indicat-
ing that the signiﬁcant association between gene expres-
sion and DNA methylation is speciﬁc and not due to
dexamethasone.
DNA Methylation age and case-control status
PD is a strong stressor for the people affected and so far
no studies have been carried out to determine whether
patients affected by PD also develop age acceleration. To
Fig. 1 Manhattan plot of the Panic Disorder EWAS in females (meta-analysis results): the x-axis shows chromosomal position and the y-
axis shows −log10 (P). The red line represents the multiple test threshold (P < 1.09 × 10−7)
Fig. 2 Box plot of DNA methylation levels for the genome-wide
signiﬁcant CpG in the discovery (P-adj = 0.046) and replication sample
(P = 0.035)
Table 2 Targeted gene analysis results for the signiﬁcant
CpGs
Sample Gene CpG P-adj
Meta-analysis
Whole SGK1 cg00959636 0.035
Males FHIT cg07351758 0.010
HTR2A cg09361691 0.015
cg06476131 0.029
Females ADCYAP1(PACAP) cg13940693 0.010
HTR1A cg16280141 0.041
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answer this question, we compared the Δ-age of PD
patients with healthy controls in the whole discovery (N
= 165, P= 0.980) and replication sample (N= 300, P=
0.282) and found no signiﬁcant differences. We then
stratiﬁed for gender and found no signiﬁcant results in
males (discovery: N= 68, P= 0.835; replication: N= 95,
P= 0.467) as well as in females (discovery: N= 97, P=
0.964; replication: N= 204, P= 0.402) (Fig. 4, Supple-
mentary Fig. S7).
Discussion
Genome-wide association of whole blood DNA
methylation with PD cases and matched controls identi-
ﬁed a locus (cg07308824), which was hypermethylated in
female PD patients compared to healthy controls. This
locus was also associated with case-control status in
females in another independent sample and results were
further conﬁrmed with a meta-analysis (N= 301). No
methylation differences were identiﬁed at genome-wide
level taking both genders together. This is the ﬁrst and
biggest EWAS for PD in a population with European
background.
The methylation locus that we identiﬁed in females is
located in the intragenic and enhancer region64 of the
Homo sapiens headcase homolog (Drosophila) (HECA)
gene on Chromosome 6. The HECA gene is a cell cycle
regulator and may play an important role in human
cancers, e.g., hepatocellular carcinoma65; however, only a
few publications about this gene are available to date. The
potential functional relevance of cg07308824 was further
investigated in the UCSC Genome Browser64. An overlap
was observed between the location of cg07308824 probe
and histone 3 lysine 27 acetylation (H3K27Ac) on seven
cell lines from ENCODE66 (Fig. 5). H3K27Ac was pre-
viously found near to active regulatory elements sug-
gesting that the sequence where the probe is located is
functional67. The HECA gene is expressed in brain at
lower levels compared to blood (Supplementary Fig. S8)
but we could not see any correlation between the
methylation levels of the signiﬁcant CpG found in blood
and brain, which could indicate that the relevance of these
results might be limited to blood. No signiﬁcant correla-
tions were found between cg07308824 methylation levels
and four different brain regions (i.e., prefrontal cortex,
superior temporal gyrus, entorhinal cortex and
Fig. 3 Scatterplot showing the association between DNA methylation
(x-axis, beta values) and gene-expression (y-axis, VSN normalized array
probe intensity) in an independent female sample at baseline (P =
0.046) and after induction by dexamethasone (P = 0.029)
Fig. 4 Violin plots of Δ-age by case-control status in the discovery sample. From the left: whole sample (P = 0.980), males only (P = 0.835), and
females only (P = 0.964)
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cerebellum) in a linear regression model using a publicly
available data set16(Supplementary Fig. S9).
It is noteworthy considering that methylation levels of
the identiﬁed locus showed a signiﬁcant correlation with
gene expression levels of the HECA gene in another
independent female sample, which points to the func-
tional relevance of the observed methylation change. The
fact that the direction of the association is positive (higher
gene expression correlated with higher methylation) may
be explained by the intragenic location of the signiﬁcant
locus. It has indeed previously been shown68 that a
positive correlation with gene expression is expected for
CpG probes located in the body of the gene and a negative
correlation is expected for CpG probes located close to a
gene’s TSS. The authors also report that however this is
only partially veriﬁed, with one-third of the latter type
showing a positive correlation and nearly half of the for-
mer type showing a negative correlation.
Notably, the signiﬁcant changes in DNA methylation
presented here are small with less than 1% difference
(0.08%) but replicable. While the functional relevance of
such small changes is debatable, these effect sizes are in
line with other EWAS in psychiatry, including the recent
small Japanese EWAS in PD22, where 40 signiﬁcant CpGs
with overall low methylation (mostly under 0.05%) dif-
ferences have been detected. Sex-speciﬁc associations
were not reported, most likely because of the small sample
size. Furthermore, similar effect sizes were observed in
other methylome studies of psychiatric disorders (schi-
zophrenia24) and other complex diseases (rheumatoid
arthritis69, multiple sclerosis70 and Alzheimer’s disease71).
The EWAS in schizophrenia is largest EWAS in the
psychiatric ﬁeld to date, with 689 schizophrenia patients
and 645 controls included in the analysis and shows
methylation differences lower than 0.02% that replicate in
an independent cohort. More work needs to be performed
to understand what contributes to these small differences
(e.g., slight differences in cell composition, genotype dif-
ferences or differences in environmental exposures) and if
they are informative beyond serving as biomarker.
Female-speciﬁc DNA methylation changes in PD have
been previously shown both in mice72 and in humans. A
female-speciﬁc association and/or correlation of negative
life events with decreased overall methylation levels has
been shown for GAD1 and MAOA20, 73. In contrast,
female-speciﬁc effects in terms of increased methylation
levels of promoter region were observed in the FOXP3
gene for PD18. Sex-speciﬁc ﬁndings regarding the
methylation pattern have been also detected in depres-
sion, which is highly comorbid with PD, and psychosis74,
75.
Interestingly, the disease association analysis shows an
enrichment for psychiatric disorders in the whole sample
and in females, but not in males.
In our analysis with Comb-P, no evidence for clusters of
differential methylation per gene could be detected,
Fig. 5 Annotation of the genome-wide signiﬁcant CpG located in the HECA gene. The top panel contains the HECA gene model, located on Chr
6. The other two panels show the genome-wide signiﬁcant CpG and the CpG island where the CpG is located. The bottom panel shows the levels of
enrichment of the H3K27Ac mark in the HECA gene. Data were obtained from UCSC Genome Browser and plotted using the R package Gviz87
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indicating that associated CpGs do not have adjacent
signals. The genome-wide ﬁndings are thus not supported
by DMR analysis. However, the structure of the 450k
Illumina array has many loci that are only interrogated
with single CpGs, especially in enhancer regions, so that
single signiﬁcant CpGs could reﬂect a differentially
methylated region, but since no adjacent CpGs are pro-
bed, this cannot be assessed using only array data. Here
bisulﬁte sequencing approaches are needed.
One of the limitation of the study is that we could not
correct for the smoking status of the subjects, due to lack
of information. We veriﬁed though that our signiﬁcant
genome-wide hit was not one of the top-associated CpGs
in the biggest EWAS for cigarette smoking76. Another
limitation is the lower number of males compared to
females, which is due to the higher prevalence of the
disease in the latter. This might also explain why no sig-
niﬁcant results were found in the male subset but only in
females. For this reason a bigger study with a higher
number of subjects, with possibly the same ratio between
genders, is necessary in order to conﬁrm the sex-
speciﬁcity of our ﬁndings.
We have to point out that we observe increased lambdas
in the QQ plots of the replication sample despite cor-
rection for population stratiﬁcation and methodological
issues, such as DNA extraction and batch effects. It is
noteworthy that female subjects of the replication sample
seem to contribute to the higher inﬂation in our study.
Other previously published EWAS in psychiatric dis-
orders have shown similar or even higher inﬂation24,25, 77–
79. The different sample size of discovery and replication
sample as well as between female and male subjects might
be one reason for these effects. The sample size of female
subjects is doubled in the replication sample (97 vs. 204).
If we extrapolate the inﬂation factor from discovery to
replication sample80, we see an increase of lambda to 1.11.
In our study, we saw the association in the HECA gene
ﬁrst in the discovery sample which showed only moderate
inﬂation and could then conﬁrm the ﬁnding in the second
sample and meta-analysis, suggesting that this ﬁnding
cannot be attributed just to the inﬂation effects in the
replication sample. Additionally, if we correct for popu-
lation stratiﬁcation using the inﬂation factor qualitatively
results are not altered.
A targeted gene approach was subsequently applied,
with the aim of investigating if genes previously associated
with PD or anxiety-related phenotypes are affected at the
methylation level. Five of the genes we analyzed, i.e.,
HTR1A, HTR2A, ADCYAP1 (pituitary adenylate cyclase-
activating polypeptide (PACAP)), FHIT and SGK1 showed
different methylation patterns in PD patients compared to
controls. For these genes, the evidence for a correlation
with anxiety disorders at the genetic level could be con-
ﬁrmed in our data at the epigenetic level. SGK1 (serum/
glucocorticoid regulated kinase 1) is one of the key player
in the mediation of fast and chronic stress response and,
therefore, could be implicated in the transition of the
environmental stress inﬂuences via methylation43. It
seems to play a role in the expression of conditioned fear
in the animal model27 and is one target of miRNAs in the
glucocorticoid pathway affecting neurogenesis and lead-
ing to anxiogenic and depressiogenic behavior in mice81.
Additional evidence from human studies point to the
implication of this gene in the pathophysiology of trau-
matic stress, e.g., PTSD82 and our results point to a pos-
sible involvement in PD as well. The second gene which is
implicated in the stress response regulation is PACAP.
Ressler et al. could demonstrate a female-speciﬁc sig-
niﬁcant correlation of the PACAP38 peptide concentra-
tion in blood with PTSD symptoms and diagnosis83. In
line with these previous ﬁndings, we could also demon-
strate a female-speciﬁc signiﬁcant methylation difference
in one locus between cases and controls, suggesting that
this gene may play an important role in long-lasting stress
dependent pathophysiology in PD or other anxiety dis-
orders. Similarly, a female-speciﬁc methylation difference
could be shown for the gene HTR1A. This serotonin
receptor is the most abundant of all serotonin receptors in
the brain and HTR1A variants have been shown to be
associated with depression and defensive behavior in PD
patients41. So far, there is no evidence for gender-speciﬁc
implication of HTR1A gene in PD or other mental dis-
orders. There are instead already previous studies show-
ing an association of HTR2A and PD7, 84, and supporting
evidence comes from our results in males. Similarly,
variants in the gene FHIT (fragile histidine triad) were
nominally associated in GWAS studies with anxiety85 and
PD5, and were not gender-speciﬁc. In a recent huge meta-
analysis for broad depression phenotype, several variants
in FHIT were among the most signiﬁcant hits86. However,
there was no difference in the burden of depressive
symptoms or depression diagnosis between the male and
female group in our study, therefore, we cannot refer our
ﬁnding to depression as bias. For HTR1A, HTR2A and
FHIT, gender-speciﬁc effects presented here need to be
replicated and elucidated in further studies.
In the targeted gene analysis we observe ﬁve signiﬁcant
results, which is more than expected by chance (2–3
expected by chance). We corrected gene-wide because
each gene was regarded as separate analysis driven by the
positive evidence for association with anxiety phenotypes.
The results might be biased by the selection of the can-
didate gene itself as one limitation of the gene-targeted
approach. Therefore, these ﬁndings, while supporting
previous results, have to be taken with caution and
replicated elsewhere.
Another aim of the study was to determine the effect of
PD on epigenetic aging, as measured with the epigenetic
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clock58. We found no differences between PD patients
and healthy controls in the discovery and replication
sample, also when separated by gender. This might be
explained by the heterogeneity of the samples in terms of
age. It was showed by Zannas et al.61 that the effect of
personal life stress on Δ-age is stronger in older as com-
pared to younger people. This suggests that the effects in
our study, if presents, might be diluted by the age-range.
Additionally, the effect sizes of PD on epigenetic age
might be low and higher sample sizes are needed to detect
signiﬁcant changes. As cumulative lifetime stress has been
shown to contribute to faster epigenetic aging61, analysis
of other phenotypes, such as number of panic attacks or
duration of the disorder, could be more effective in
uncovering epigenetic aging effects of PD. In summary,
our study examines epigenome-wide differences in per-
ipheral blood for PD patients. Our results point to pos-
sible sex-speciﬁc methylation changes in the HECA gene
for PD but overall highlight that this disorder is not
associated with extensive changes in DNA methylation
pattern in peripheral blood.
Acknowledgements
We thank Maik Ködel and Susann Sauer for the DNA extraction, Torsten Klengel
for his assistance in performing the experiments and Monika Rex-Haffner for
her technical assistance.
This study was ﬁnanced by ERA-NET NEURON.
Competing interests
The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional
claims in published maps and institutional afﬁliations.
Supplementary Information
The online version of this article (https://doi.org/10.1038/s41398-017-0026-1)
contains supplementary material.
Received: 20 March 2017 Revised: 23 August 2017 Accepted: 23 August
2017
References
1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental
Disorders (DSM-5®) (American Psychiatric Publishing, Arlington, VA, 2013).
2. Goodwin, R. D. & Rosi, S. et al. The epidemiology of panic disorder and
agoraphobia in Europe. Eur. Neuropsychopharmacol. 15, 435–443 (2005).
3. Noyes, R. Jr et al. Relationship between panic disorder and agoraphobia. A
family study. Arch. Gen. Psychiatry 43, 227–232 (1986).
4. Hettema, J. M., Neale, M. C. & Kendler, K. S. A. Review and meta-analysis of the
genetic epidemiology of anxiety disorders. Am. J. Psychiatry 158, 1568–1578
(2001).
5. Erhardt, A. et al. TMEM132D, a new candidate for anxiety phenotypes: evi-
dence from human and mouse studies. Mol. Psychiatry 16, 647–663 (2011).
6. Erhardt, A. et al. Replication and meta-analysis of TMEM132D gene variants in
panic disorder. Transl. Psychiatry 2, e156 (2012).
7. Howe, A. S. et al. Candidate genes in panic disorder: meta-analyses of 23
common variants in major anxiogenic pathways. Mol. Psychiatry 21, 665–679
(2016).
8. Weber, H. et al. Allelic variation in CRHR1 predisposes to panic disorder:
evidence for biased fear processing. Mol. Psychiatry 21, 813–822 (2016).
9. Gottschalk, M. G. & Domschke, K. Novel developments in genetic and epi-
genetic mechanisms of anxiety. Curr. Opin. Psychiatry 29, 32–38 (2016).
10. Teh, A. L. et al. The effect of genotype and in utero environment on inter-
individual variation in neonate DNA methylomes. Genome Res. 24, 1064–1074
(2014).
11. Torvik, F. A. et al. Longitudinal associations between social anxiety disorder
and avoidant personality disorder: a twin study. J. Abnorm. Psychol. 125,
114–124 (2016).
12. South, S. C. et al A population based twin study of DSM-5 maladaptive
personality domains. Personal Disord. 8, 366–375 (2017).
13. Kendler, K. S. et al A National Swedish Twin-Sibling Study of alcohol use
disorders. Twin Res. Hum. Genet. 19, 430–437 (2016).
14. Slatkin, M. Epigenetic inheritance and the missing heritability problem.
Genetics 182, 845–850 (2009).
15. Klengel, T. & Binder, E. B. Epigenetics of stress-related psychiatric disorders and
gene × environment interactions. Neuron 86, 1343–1357 (2015).
16. Hannon, E., Lunnon, K., Schalkwyk, L. & Mill, J. Interindividual methylomic
variation across blood, cortex, and cerebellum: implications for epigenetic
studies of neurological and neuropsychiatric phenotypes. Epigenetics 10,
1024–1032 (2015).
17. Farre, P., Jones, M. J., Meaney, M. J., Emberly, E., Turecki, G. & Kobor, M. S.
Concordant and discordant DNA methylation signatures of aging in human
blood and brain. Epigenetics Chromatin 8, 19 (2015).
18. Prelog, M. et al. Hypermethylation of FOXP3 promoter and premature aging
of the immune system in female patients with panic disorder? PLoS. One 11,
e0157930 (2016).
19. Ziegler, C. et al. MAOA gene hypomethylation in panic disorder-reversibility of
an epigenetic risk pattern by psychotherapy. Transl. Psychiatry 6, e773 (2016).
20. Domschke, K. et al. Epigenetic signature of panic disorder: a role of glutamate
decarboxylase 1 (GAD1) DNA hypomethylation? Prog. Neuropsychopharmacol.
Biol. Psychiatry 46, 189–196 (2013).
21. Bayles, R. et al. Methylation of the SLC6a2 gene promoter in major depression
and panic disorder. PLoS. One 8, e83223 (2013).
22. Shimada-Sugimoto, M. et al. Epigenome-wide association study of DNA
methylation in panic disorder. Clin. Epigenetics 9, 6 (2017).
23. Youseﬁ, P. et al. Sex differences in DNA methylation assessed by 450 K
BeadChip in newborns. BMC Genom. 16, 911 (2015).
24. Montano, C. et al. Association of DNA methylation differences with schizo-
phrenia in an Epigenome-Wide Association Study. JAMA Psychiatry 73,
506–514 (2016).
25. Houtepen, L. C., van Bergen, A. H., Vinkers, C. H. & Boks, M. P. DNA methylation
signatures of mood stabilizers and antipsychotics in bipolar disorder. Epige-
nomics 8, 197–208 (2016).
26. Nieto, S. J., Patriquin, M. A., Nielsen, D. A. & Kosten, T. A. Don’t worry; be
informed about the epigenetics of anxiety. Pharmacol. Biochem. Behav. 146-
147, 60–72 (2016).
27. Knoll, A. T., Halladay, L. R., Holmes, A. J. & Levitt, P. Quantitative trait loci and a
novel genetic candidate for fear learning. J. Neurosci. 36, 6258–6268 (2016).
28. Horvath, S. et al. Decreased epigenetic age of PBMCs from Italian semi-
supercentenarians and their offspring. Aging (Albany NY) 7, 1159–1170 (2015).
29. Marioni, R. E. et al. DNA methylation age of blood predicts all-cause mortality
in later life. Genome Biol. 16, 25 (2015).
30. Chen, B. H. et al. DNA methylation-based measures of biological age: meta-
analysis predicting time to death. Aging (Albany NY) 8, 1844–1859 (2016).
31. Christiansen, L. et al. DNA methylation age is associated with mortality in a
longitudinal Danish twin study. Aging Cell. 15, 149–154 (2016).
32. Wittchen, H. U. & Pﬁster, H. DIA-X-Interviews: Manual für Screening-Verfahren
und Interview (Swets & Zeitlinger, Frankfurt, 1997).
33. Chen, Y. A. et al. Discovery of cross-reactive probes and polymorphic CpGs in
the Illumina Inﬁnium HumanMethylation450 microarray. Epigenetics 8,
203–209 (2013).
34. Fortin, J. P. et al. Functional normalization of 450k methylation array data
improves replication in large cancer studies. Genome Biol. 15, 503 (2014).
35. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics 8, 118–127 (2007).
36. Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations.
Bioinformatics 28, 1353–1358 (2012).
37. Houseman, E. A. et al. DNA methylation arrays as surrogate measures of cell
mixture distribution. BMC Bioinforma. 13, 86 (2012).
38. Purcell, S. et al. PLINK: a tool set for whole-genome association and
population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
Iurato et al. Translational Psychiatry  (2017) 7:1287 Page 9 of 10
Translational Psychiatry
39. Pedersen, B. S., Schwartz, D. A. & Yang, KechrisK. J. IV Comb-p: software for
combining, analyzing, grouping and correcting spatially correlated P-values.
Bioinformatics 28, 2986–2988 (2012).
40. Blaya, C. et al. Panic disorder and serotonergic genes (SLC6A4, HTR1A and
HTR2A): association and interaction with childhood trauma and parenting.
Neurosci. Lett. 485, 11–15 (2010).
41. Straube, B. et al. The functional −1019C/G HTR1A polymorphism and
mechanisms of fear. Transl. Psychiatry 4, e490 (2014).
42. Ressler, K. J. et al. Post-traumatic stress disorder is associated with PACAP and
the PAC1 receptor. Nature 470, 492–497 (2011).
43. Cattaneo, A. & Riva, M. A. Stress-induced mechanisms in mental illness: a role
for glucocorticoid signalling. J. Steroid Biochem. Mol. Biol. 160, 169–174 (2016).
44. Zannas, A. S., Wiechmann, T., Gassen, N. C. & Binder, E. B. Gene-stress-
epigenetic regulation of fkbp5: clinical and translational implications. Neu-
ropsychopharmacology 41, 261–274 (2016).
45. Han, E. J. et al. Evidence for association between the brain-derived neuro-
trophic factor gene and panic disorder: a novel haplotype analysis. Psychiatry
Investig. 12, 112–117 (2015).
46. Konishi, Y. et al. Genexgenexgender interaction of BDNF and COMT geno-
types associated with panic disorder. Prog. Neuropsychopharmacol. Biol. Psy-
chiatry 51, 119–125 (2014).
47. Ziegler, C. et al. Oxytocin receptor gene methylation: converging multilevel
evidence for a role in social anxiety. Neuropsychopharmacology 40, 1528–1538
(2015).
48. Desbonnet, L. et al. Physiological and behavioural responsivity to stress and
anxiogenic stimuli in COMT-deﬁcient mice. Behav. Brain Res. 228, 351–358
(2012).
49. Leonard, S. K. et al. Pharmacology of neuropeptide S in mice: therapeutic
relevance to anxiety disorders. Psychopharmacol. (Berl.). 197, 601–611 (2008).
50. Benekareddy, M., Vadodaria, K. C., Nair, A. R. & Vaidya, V. A. Postnatal serotonin
type 2 receptor blockade prevents the emergence of anxiety behavior, dys-
regulated stress-induced immediate early gene responses, and speciﬁc tran-
scriptional changes that arise following early life stress. Biol. Psychiatry 70,
1024–1032 (2011).
51. Mustafa, T., Jiang, S. Z., Eiden, A. M., Weihe, E., Thistlethwaite, I. & Eiden, L. E.
Impact of PACAP and PAC1 receptor deﬁciency on the neurochemical and
behavioral effects of acute and chronic restraint stress in male C57BL/6 mice.
Stress 18, 408–418 (2015).
52. Bahi, A., Al Mansouri, S. & Al Maamari, E. Nucleus accumbens lentiviral-
mediated gain of function of the oxytocin receptor regulates anxiety- and
ethanol-related behaviors in adult mice. Physiol. Behav. 164, 249–258 (2016).
53. Wang, J., Duncan, D., Shi, Z. & Zhang, B. WEB-based GEne SeT AnaLysis Toolkit
(WebGestalt). Nucleic Acids Res. 41, W77–W83 (2013).
54. Zhang, B., Kirov, S. & Snoddy, J. WebGestalt: an integrated system for exploring
gene sets in various biological contexts. Nucleic Acids Res. 33, W741–W748
(2005).
55. Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists. Nucleic
Acids Res. 37, 1–13 (2009).
56. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4,
44–57 (2009).
57. Yu, G., Wang, L. G., Yan, G. R. & He, Q. Y. DOSE: an R/Bioconductor package for
disease ontology semantic and enrichment analysis. Bioinformatics 31,
608–609 (2015).
58. Horvath, S. DNA methylation age of human tissues and cell types. Genome
Biol. 14, R115 (2013).
59. Teschendorff, A. E. et al. A beta-mixture quantile normalization method for
correcting probe design bias in Illumina Inﬁnium 450 k DNA methylation data.
Bioinformatics 29, 189–196 (2013).
60. Arloth, J. et al. Genetic differences in the immediate transcriptome response to
stress predict risk-related brain function and psychiatric disorders. Neuron 86,
1189–1202 (2015).
61. Zannas, A. S. et al. Lifetime stress accelerates epigenetic aging in an urban,
African American cohort: relevance of glucocorticoid signaling. Genome Biol.
16, 266 (2015).
62. Chikina, M., Zaslavsky, E. & Sealfon, S. C. CellCODE: a robust latent variable
approach to differential expression analysis for heterogeneous cell popula-
tions. Bioinformatics 31, 1584–1591 (2015).
63. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models
Using lme4. J. Stat. Softw. 67, 10.18637/jss.v067.i01 (2015).
64. Kent, W., Sugnet, C., Furey, T., Roskin, K., Pringle, T. & Zahler, A. et al. The human
genome browser at UCSC. Genome Res. 12, 996–1006 (2002).
65. Wang, J. et al. The human homolog of drosophila headcase acts as a tumor
suppressor through its blocking effect on the cell cycle in hepatocellular
carcinoma. PLoS. One 10, e0137579 (2015).
66. Rosenbloom, K. R. et al ENCODE Data in the UCGC Genome Browser. Nucleic
Acids Res. 41, D56–D63 (2013).
67. Creyghton, M. P. et al. Histone H3K27ac separates active from poised
enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 107,
21931–21936 (2010).
68. Wagner, J. R., Busche, S., Ge, B., Kwan, T., Pastinen, T. & Blanchette, M. The
relationship between DNA methylation, genetic and expression inter-
individual variation in untransformed human ﬁbroblasts. Genome Biol. 15,
R37 (2014).
69. Liu, Y. et al. Epigenome-wide association data implicate DNA methylation as
an intermediary of genetic risk in rheumatoid arthritis. Nat. Biotechnol. 31,
142–147 (2013).
70. Huynh, J. L. et al. Epigenome-wide differences in pathology-free regions of
multiple sclerosis-affected brains. Nat. Neurosci. 17, 121–130 (2014).
71. Lunnon, K. et al. Methylomic proﬁling implicates cortical deregulation of ANK1
in Alzheimer’s disease. Nat. Neurosci. 17, 1164–1170 (2014).
72. Papale, L. A. et al. Sex-speciﬁc hippocampal 5-hydroxymethylcytosine is dis-
rupted in response to acute stress. Neurobiol. Dis. 96, 54–66 (2016).
73. Domschke, K. et al. Monoamine oxidase A gene DNA hypomethylation—a
risk factor for panic disorder? Int. J. Neuropsychopharmacol. 15, 1217–1228
(2012).
74. Byrne, E. M. et al. Monozygotic twins affected with major depressive disorder
have greater variance in methylation than their unaffected co-twin. Transl.
Psychiatry 3, e269 (2013).
75. Melas, P. A. et al. Genetic and epigenetic associations of MAOA and NR3C1
with depression and childhood adversities. Int. J. Neuropsychopharmacol. 16,
1513–1528 (2013).
76. Joehanes, R. et al. Epigenetic signatures of cigarette smoking. Circ. Cardiovasc.
Genet. 9, 436–447 (2016).
77. Cecil, C. A. et al. Epigenetic signatures of childhood abuse and neglect:
implications for psychiatric vulnerability. J. Psychiatr. Res. 83, 184–194 (2016).
78. Houtepen, L. C. et al. Genome-wide DNA methylation levels and altered
cortisol stress reactivity following childhood trauma in humans. Nat. Commun.
7, 10967 (2016).
79. Viana, J. et al. Schizophrenia-associated methylomic variation: molecular sig-
natures of disease and polygenic risk burden across multiple brain regions.
Hum. Mol. Genet. 26, 210–225 (2017).
80. Freedman, M. L. et al. Assessing the impact of population stratiﬁcation on
genetic association studies. Nat. Genet. 36, 388–393 (2004).
81. Jin, J. et al. miR-17-92 cluster regulates adult hippocampal neurogenesis,
anxiety, and depression. Cell. Rep. 16, 1653–1663 (2016).
82. Licznerski, P. et al Decreased SGK1 expression and function contributes to
behavioral deﬁcits induced by traumatic stress. PLoS. Biol. 13, e1002282 (2015).
83. Dias, B. G. & Ressler, K. J. PACAP and the PAC1 receptor in post-traumatic stress
disorder. Neuropsychopharmacology 38, 245–246 (2013).
84. Unschuld, P. G. et al. Polymorphisms in the serotonin receptor gene HTR2A
are associated with quantitative traits in panic disorder. Am. J. Med. Genet. B.
Neuropsychiatr. Genet. 144b, 424–429 (2007).
85. Luciano, M. et al. Genome-wide association uncovers shared genetic effects
among personality traits and mood states. Am. J. Med. Genet. B. Neuropsychiatr.
Genet. 159b, 684–695 (2012).
86. Direk, N. et al An analysis of two genome-wide association meta-analyses
identiﬁes a new locus for broad depression phenotype. Biol. Psychiatry 82,
322–329 (2017).
87. Hahne, F. & Ivanek, R. Visualizing genomic data using Gviz and bioconductor.
Methods Mol. Biol. 1418, 335–351 (2016).
Iurato et al. Translational Psychiatry  (2017) 7:1287 Page 10 of 10
Translational Psychiatry
